Skip to main content
Top
Published in: Journal of Nuclear Cardiology 5/2018

01-10-2018 | Editorial

Setting the stage for the next step in cardiac amyloidosis imaging: Serial quantitative studies to assess disease activity

Authors: Prem Soman, MD, PhD, FRCP (UK), FACC, Ahmad Masri, MD

Published in: Journal of Nuclear Cardiology | Issue 5/2018

Login to get access

Excerpt

The term “amyloid” refers to misfolded proteins that tend to aggregate into fibrils, usually with a beta-pleated structural conformation.1 The latter imparts the characteristic apple-green birefringence when stained with Congo-red and viewed under polarized light. The term is attributed to Rudolf Virchow who used it to describe the observed “lardaceous” infiltration of tissues, which was incorrectly thought to be a substance derived from starch (from latin “amylum”).2 Due to already established widespread use, the nomenclature persisted even after the proteinaceous origin of amyloid was subsequently identified. The deposition of amyloid proteins is the basis of several recognized organ-specific and systemic amyloidosis syndromes, neurodegenerative disorders, and prion diseases.3
Literature
1.
go back to reference Toyama BH, Weissman JS. Amyloid structure: Conformational diversity and consequences. Annu Rev Biochem 2011;80:557-85.CrossRef Toyama BH, Weissman JS. Amyloid structure: Conformational diversity and consequences. Annu Rev Biochem 2011;80:557-85.CrossRef
2.
3.
go back to reference Pulawski W, Ghoshdastider U, Andrisano V, Filipek S. Ubiquitous amyloids. Appl Biochem Biotechnol 2012;166:1626-43.CrossRef Pulawski W, Ghoshdastider U, Andrisano V, Filipek S. Ubiquitous amyloids. Appl Biochem Biotechnol 2012;166:1626-43.CrossRef
4.
go back to reference Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286-300.CrossRef Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286-300.CrossRef
5.
go back to reference Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012;98:1442-8.CrossRef Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012;98:1442-8.CrossRef
6.
go back to reference Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93.CrossRef Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93.CrossRef
7.
go back to reference Gertz MA, Brown ML, Hauser MF, Kyle RA. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med 1987;147:1039-44.CrossRef Gertz MA, Brown ML, Hauser MF, Kyle RA. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med 1987;147:1039-44.CrossRef
8.
go back to reference Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133(24):2404-12.CrossRef Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133(24):2404-12.CrossRef
9.
go back to reference González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585-94.CrossRef González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585-94.CrossRef
10.
go back to reference Castaño A, Bokhari S, Maurer MS. Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2595-7.CrossRef Castaño A, Bokhari S, Maurer MS. Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2595-7.CrossRef
11.
12.
go back to reference Castano A, DeLuca A, Weinberg R, et al. Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol 2016;23:1355-63.CrossRef Castano A, DeLuca A, Weinberg R, et al. Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol 2016;23:1355-63.CrossRef
13.
go back to reference Kristen AV, Brokbals E, Aus dem Siepen F, et al. Cardiac amyloid load: A prognostic and predictive biomarker in patients with light-chain amyloidosis. J Am Coll Cardiol 2016;68:13-24.CrossRef Kristen AV, Brokbals E, Aus dem Siepen F, et al. Cardiac amyloid load: A prognostic and predictive biomarker in patients with light-chain amyloidosis. J Am Coll Cardiol 2016;68:13-24.CrossRef
14.
go back to reference Ruberg FL, Fontana M, Gillmore JD. Should histologic determination of amyloid load determine management decisions in light-chain amyloidosis? J Am Coll Cardiol 2016;68:2493-4.CrossRef Ruberg FL, Fontana M, Gillmore JD. Should histologic determination of amyloid load determine management decisions in light-chain amyloidosis? J Am Coll Cardiol 2016;68:2493-4.CrossRef
15.
go back to reference Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015;132:1570-9.CrossRef Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015;132:1570-9.CrossRef
16.
go back to reference Kristen AV, Brokbals E, Aus dem Siepen F, et al. Reply: Should histologic determination of amyloid load determine management decisions in light-chain amyloidosis? J Am Coll Cardiol 2016;68:2494-5.CrossRef Kristen AV, Brokbals E, Aus dem Siepen F, et al. Reply: Should histologic determination of amyloid load determine management decisions in light-chain amyloidosis? J Am Coll Cardiol 2016;68:2494-5.CrossRef
17.
go back to reference Kinahan PE, Fletcher JW. PET/CT standardized uptake values (SUVs) in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 2010;31:496-505.CrossRef Kinahan PE, Fletcher JW. PET/CT standardized uptake values (SUVs) in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 2010;31:496-505.CrossRef
18.
go back to reference Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45:1519-27.PubMed Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45:1519-27.PubMed
19.
go back to reference Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-95. Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-95.
20.
go back to reference Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 2014;41:1652-62.CrossRef Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 2014;41:1652-62.CrossRef
21.
go back to reference Lee SP, Lee ES, Choi H, et al. 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging 2015;8:50-9.CrossRef Lee SP, Lee ES, Choi H, et al. 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging 2015;8:50-9.CrossRef
22.
go back to reference Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.CrossRef Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.CrossRef
Metadata
Title
Setting the stage for the next step in cardiac amyloidosis imaging: Serial quantitative studies to assess disease activity
Authors
Prem Soman, MD, PhD, FRCP (UK), FACC
Ahmad Masri, MD
Publication date
01-10-2018
Publisher
Springer US
Published in
Journal of Nuclear Cardiology / Issue 5/2018
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-017-0846-7

Other articles of this Issue 5/2018

Journal of Nuclear Cardiology 5/2018 Go to the issue